ArticleFrontiers in oncology2026
Unveiling trends in malignant neoplasms of bone and articular cartilage mortality in the United States (1999-2023): a CDC WONDER perspective.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant neoplasms of bone and articular cartilage (MNBAC) are rare but highly fatal cancers contributing to global cancer mortality. This study analyzed demographic and regional patterns of MNBAC mortality in the United States from 1999 to 2023 to identify high-risk populations for targeted interventions. Methods: We extracted mortality data from the CDC WONDER database using ICD-10 codes C40-C41. Crude and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated by gender, census region, race, and urbanization using R software (version 4.4.2). Joinpoint regression was employed to evaluate annual percentage changes (APCs). Results: From 1999 to 2023, MNBAC mortality trends varied across demographic groups. The South showed the highest AAMR (0.60 in 1999, 95% CI: 0.54 to 0.66; 0.68 in 2023, 95% CI: 0.63 to 0.73), while the West demonstrated the steepest increase (AAPC = 1.33, 95% CI: 0.92 to 1.74). Age analysis revealed the most significant crude mortality rate increases among individuals aged ≥75 years (AAPC = 0.90 for 75-84; AAPC = 1.89 for 85+), with accelerated growth after 2012 (APC = 2.52 and 4.34, respectively). Among racial groups, Hispanics showed the fastest AAMR increase (AAPC = 1.01, 95% CI: 0.36 to 1.66), though non-Hispanic whites maintained the highest AAMR (0.68, 95% CI: 0.64 to 0.72). Metropolitan areas exhibited greater AAMR increases than non-metropolitan areas (AAPC = 0.84 vs. 0.27). Males consistently showed higher AAMRs than females (0.65 vs. 0.45 in 1999; 0.72 vs. 0.53 in 2023; Conclusion: Significant disparities exist in MNBAC mortality, with elevated rates among males, Southerners, and non-Hispanic whites. Notable increases occurred in the West, among those aged ≥75 years, Hispanics, and metropolitan residents. These findings underscore the need for targeted interventions to improve outcomes and reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.